Journal of Hematology & Oncology (Feb 2021)
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
- Musa Yilmaz,
- Mansour Alfayez,
- Courtney D. DiNardo,
- Gautam Borthakur,
- Tapan M. Kadia,
- Marina Y. Konopleva,
- Sanam Loghavi,
- Rashmi Kanagal-Shamanna,
- Keyur P. Patel,
- Elias J. Jabbour,
- Guillermo Garcia‑Manero,
- Naveen Pemmaraju,
- Sherry A. Pierce,
- Issa Ghayas,
- Nicholas J. Short,
- Guillermo Montalban-Bravo,
- Koichi Takahashi,
- Rita Assi,
- Ahmad S. Alotaibi,
- Maro Ohanian,
- Michael Andreeff,
- Jorge E. Cortes,
- Hagop M. Kantarjian,
- Farhad Ravandi,
- Naval G. Daver
Affiliations
- Musa Yilmaz
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Mansour Alfayez
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Courtney D. DiNardo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Gautam Borthakur
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Tapan M. Kadia
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Marina Y. Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Sanam Loghavi
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center
- Rashmi Kanagal-Shamanna
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center
- Keyur P. Patel
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center
- Elias J. Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Guillermo Garcia‑Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Naveen Pemmaraju
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Sherry A. Pierce
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Issa Ghayas
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Nicholas J. Short
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Guillermo Montalban-Bravo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Koichi Takahashi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Rita Assi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Ahmad S. Alotaibi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Maro Ohanian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Michael Andreeff
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Jorge E. Cortes
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Hagop M. Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Farhad Ravandi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Naval G. Daver
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1186/s13045-020-01023-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 2
Abstract
An amendment to this paper has been published and can be accessed via the original article.
